Cellular DNA is subjected to continual attack, both by reactive species inside cells and by environmental agents. Toxic and mutagenic consequences are minimized by distinct pathways of repair, and 130 known human DNA repair genes are described here. Notable features presently include four enzymes that can remove uracil from DNA, seven recombination genes related to RAD51, and many recently discovered DNA polymerases that bypass damage, but only one system to remove the main DNA lesions induced by ultraviolet light. More human DNA repair genes will be found by comparison with model organisms and as common folds in three-dimensional protein structures are determined. Modulation of DNA repair should lead to clinical applications including improvement of radiotherapy and treatment with anticancer drugs and an advanced understanding of the cellular aging process.
The genetic changes that occur in cancer, whether these be mutations or alterations in levels of gene expression, become evident as changes in the phenotype of a specific cell type. In characterizing these phenotypic changes in malignancy, it is therefore important to work with the appropriate cells or cell lines. Breast cancers show the phenotype of the luminal epithelial cell (1), which can be cultured from milk, and cell lines have been developed from these milk cells which retain the luminal phenotype (2). One of these cell lines (MTSV1-7) has been used to look at the effect of overexpression of various oncogenes and proto-oncogenes on the behavioral properties of this cell type (3, 4).Overexpression of the c-ErbB2 receptor has been observed in a proportion of breast cancers and found to correlate with a poor prognosis (5), making signaling from this receptor an important parameter for investigation. To study the function of c-ErbB2 in human mammary epithelial cells, the receptor was overexpressed in MTSV1-7 cells to produce the ce-1 cell line (3). Unlike other receptors in the ErbB family, the c-ErbB2 homodimer has no known ligand, although c-ErbB2 can function as a heterodimeric receptor for the heregulin family of ligands with c-ErbB3 or c-ErbB4 or for EGF with c-ErbB1 (6 -9). Signaling from c-ErbB2 in overexpressing cells is, however, thought to be constitutive, operating through autophosphorylation of the homodimer, which forms because of overexpression (10).To look for genes whose expression is reversibly regulated by c-ErbB2 signaling as a homodimer, we have down-regulated c-ErbB2 phosphorylation using an antibody that has been shown to inhibit signaling from the receptor in breast cancer cell lines (11). In the humanized form (12), the antibody is under investigation in the clinic for the treatment of breast cancer (13). cDNAs prepared from ce-1 cells, treated or untreated with the antibody 4D5, were used to differentially screen filters from a fetal brain library using a computerized analysis (14), and a partial clone was isolated representing a novel sequence. Clones covering the full-length sequence (6.4 kb) 1 of the novel PLU-1 gene 2 were subsequently isolated by screening a breast cancer cDNA library.
Protein kinase D (PKD) is a serine/threonine kinase regulated by diacylglycerol signaling pathways with unique domain composition and enzymatic properties, still awaiting identification of its specific substrate(s). Here we have isolated, cloned, and characterized a novel protein from PC12 cells, termed Kidins220 (kinase D-interacting substrate of 220 kDa), as the first identified PKD physiological substrate. Kidins220 contains 11 ankyrin repeats and four transmembrane domains within the N-terminal region. We have shown that Kidins220 is an integral membrane protein selectively expressed in brain and neuroendocrine cells, where it concentrates at the tip of neurites. In PC12 cells, PKD coimmunoprecipitates and phosphorylates endogenous Kidins220. This phosphorylation is increased after stimulating PKD activity in vivo by phorbol-12,13-dibutyrate treatment. A constitutively active PKD mutant (PKD-S744E/S748E) phosphorylates recombinant Kindins220-VSVG in vitro in the absence of phorbol-12,13-dibutyrate. Conversely, Kidins220-VSVG phosphorylation is abolished when a dominant negative mutant of PKD (PKD-D733A) is used. Moreover, a peptide within the Kidins220 sequence, containing serine 919 in a consensus motif for PKD-specific phosphorylation, behaved as the best peptide substrate to date. Substitution of serine 919 to alanine abrogated peptide phosphorylation. Furthermore, by generating an antibody recognizing Kidins220 phosphorylated on serine 919, we show that phorbol ester treatment causes the specific phosphorylation of this residue in PC12 cells in vivo. Our results provide the first physiological substrate for PKD and indicate that Kidins220 is phosphorylated by PKD at serine 919 in vivo.Stimulation of several plasma membrane receptors by hormones, growth factors, and cytokines causes the rapid hydrolysis of phosphoinositides, which results in an increase of the lipid-derived second messenger diacylglycerol (DAG) 1 (1). DAG causes the activation of protein kinase C (PKC) (2, 3), which in turn affects several cellular processes including cell growth and differentiation, changes in cell morphology, neuronal development, and endocrine and exocrine secretion (2, 4 -6). PKC isoforms are divided into three major groups on the basis of their primary structure and biochemical properties (7-9). The conventional PKCs (␣, 1, 2, and ␥) contain a regulatory cysteine-rich domain that binds DAG and phorbol esters and a calcium binding domain responsible for the calcium-dependent modulation of their kinase activity. The novel PKCs (␦, ⑀, , and ) are sensitive to DAG or phorbol esters but are calciumindependent. The third group is known as the atypical PKCs ( and /), which are unresponsive to calcium, DAG, or phorbol esters.Protein kinase D (PKD, also known as PKC) is a serine/ threonine kinase distantly related to the PKC family. It contains a conserved DAG/phorbol ester-binding cysteine-rich domain like the classical and novel PKC isoforms but has singular enzymological and structural properties (10 -13). Unlike all oth...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.